You are here

  • Home
  • Archive
  • Volume 10, Issue 9
  • COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis

Article info

Article menu
Clinical/translational cancer immunotherapy
Original research
COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis

Authors

  • Rikke Boedker Holmstroem National Center for Cancer Immunotherapy, Department of Oncology, Copenhagen University Hospital, Herlev, DenmarkDepartment of Oncology, Copenhagen University Hospital, Herlev, Denmark PubMed articlesGoogle scholar articles
  • Ole Haagen Nielsen Department of Gastroenterology, Copenhagen University Hospital, Herlev, DenmarkDepartment of Clinical Medicine, University of Copenhagen Faculty of Health and Medical Sciences, Copenhagen, Denmark PubMed articlesGoogle scholar articles
  • Søren Jacobsen Department of Clinical Medicine, University of Copenhagen Faculty of Health and Medical Sciences, Copenhagen, DenmarkCopenhagen Lupus and Vasculitis Clinic, Copenhagen University Hospital, Copenhagen, Denmark PubMed articlesGoogle scholar articles
  • Lene Buhl Riis Department of Pathology, Copenhagen University Hospital, Herlev, Denmark PubMed articlesGoogle scholar articles
  • Susann Theile Department of Oncology, Copenhagen University Hospital, Herlev, Denmark PubMed articlesGoogle scholar articles
  • Jacob Tveiten Bjerrum Department of Gastroenterology, Copenhagen University Hospital, Herlev, DenmarkDepartment of Clinical Medicine, University of Copenhagen Faculty of Health and Medical Sciences, Copenhagen, Denmark PubMed articlesGoogle scholar articles
  • Peter Vilmann Department of Clinical Medicine, University of Copenhagen Faculty of Health and Medical Sciences, Copenhagen, DenmarkGastrounit - Division of Surgery, Copenhagen University Hospital, Herlev, Denmark PubMed articlesGoogle scholar articles
  • Julia Sidenius Johansen Department of Clinical Medicine, University of Copenhagen Faculty of Health and Medical Sciences, Copenhagen, DenmarkDepartment of Medicine, Copenhagen University Hospital, Herlev, Denmark PubMed articlesGoogle scholar articles
  • Mogens Karsbøl Boisen Department of Oncology, Copenhagen University Hospital, Herlev, Denmark PubMed articlesGoogle scholar articles
  • Rikke Helene Løvendahl Eefsen Department of Oncology, Copenhagen University Hospital, Herlev, Denmark PubMed articlesGoogle scholar articles
  • Inge Marie Svane National Center for Cancer Immunotherapy, Department of Oncology, Copenhagen University Hospital, Herlev, DenmarkDepartment of Oncology, Copenhagen University Hospital, Herlev, DenmarkDepartment of Clinical Medicine, University of Copenhagen Faculty of Health and Medical Sciences, Copenhagen, Denmark PubMed articlesGoogle scholar articles
  • Dorte Lisbet Nielsen Department of Oncology, Copenhagen University Hospital, Herlev, DenmarkDepartment of Clinical Medicine, University of Copenhagen Faculty of Health and Medical Sciences, Copenhagen, Denmark PubMed articlesGoogle scholar articles
  • Inna Markovna Chen Department of Oncology, Copenhagen University Hospital, Herlev, Denmark PubMed articlesGoogle scholar articles

Citation

Holmstroem RB, Nielsen OH, Jacobsen S, et al
COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis
Journal for ImmunoTherapy of Cancer 2022;10:e005111. doi: 10.1136/jitc-2022-005111
Online issue publication 
September 12, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.